Who is sponsoring NCT02892604?

NCT02892604 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT02892604?

Interventions in NCT02892604: insulin pump to inControl AP platform.

What condition does NCT02892604 study?

NCT02892604 studies Type 1 Diabetes.

Is NCT02892604 still recruiting?

NCT02892604 is currently terminated. Last updated 9 December 2021.

Last reviewed 2021-12-09 · How we verify

NCT02892604: IDCLTraining

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes

Terminated NA Last updated 9 December 2021

What this trial tests

NA trial testing insulin pump to inControl AP platform in Type 1 Diabetes in 3 participants. Terminated before completion.

Timeline

24 November 2015

Primary endpoint
24 June 2017

24 June 2017

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	24 November 2015
Primary completion	24 June 2017
Estimated completion	24 June 2017
Sites	1 location across France

Drugs / interventions tested

insulin pump to inControl AP platform

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 75, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A new version of the DiAs artificial pancreas (AP) system has been developed in view of wide scale outpatient trials. Denominated as inControl , it includes improved user interface and communication modules while closed-loop algorithms remain similar. During this pilot study, the investigators will evaluate this new version of AP for a two-week period during which the patients will use it for closed-loop insulin delivery 24/7 The main goal is train the clinical team with the new system and collect patient opinions on system acceptance from questionnaires. If this trial is conclusive, a randomized 6-month multicentre study including 240 patients will be initiated. A total of 5 patients will be included in this training study over a 4-week period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability.
Anderson SM, Dassau E, Raghinaru D, Lum J, et al · · 2019 · cited 17× · PMID 30649925 · DOI 10.1089/dia.2018.0308

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02892604 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 9 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02892604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing